eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Total Current Liabilities
All obligations due within one year.
eXoZymes, Inc.NASDAQ: EXOZ
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 9.6% from a year ago
Total current liabilities stood at $1.58M at the end of Q1 FY2026, up 9.6% from a year earlier and up 1.0% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.
Context
- Total current liabilities amounted to 39.4% of total assets at the end of Q1 FY2026, up 26.8 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +9.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.57M USD
- Year-over-year change
- +17.5%
- 4-year CAGR
- +40.6%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.57M | +17.5% |
| FY2024 | 2024-12-31 | 1.33M | -44.8% |
| FY2023 | 2023-12-31 | 2.42M | +280.7% |
| FY2022 | 2022-12-31 | 634.36K | +58.3% |
| FY2021 | 2021-12-31 | 400.78K | — |
Total Current Liabilities vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +9.6% is the 3rd highest of 7, against a peer median of -7.8%.
- Total current liabilities amounts to 39.4% of total assets for EXOZ, versus a peer median of 33.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $11.21M USD | +52.5% | +18.9% | 97.5% | |
| Mar 2026 | $9.57M USD | -9.6% | +0.7% | 7.9% | |
| Mar 2026 | $6.05M USD | -44.7% | +21.3% | 16.7% | |
| Mar 2026 | CA$5.42M CAD | -6.0% | +28.5% | 66.5% | |
| Mar 2026 | $5.24M USD | +263.9% | +180.9% | 49.8% | |
| Mar 2026 | $4.72M USD | -34.7% | -47.1% | 2.4% | |
EXOZeXoZymes, Inc. | Mar 2026 | $1.58M USD | +9.6% | +35.2% | 39.4% |
| Peer median (excluding EXOZ) | — | -7.8% | +20.1% | 33.3% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 547.81K | 558.57K | 66.53K | 9.72M | 3.04M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 468.35K | 809.53K | 882.32K | 737.28K | 517.36K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 30.19K | 101.14K | 264.76K | 363.79K | 382.89K |
| Total Current Assets | 1.05M | 1.47M | 1.21M | 10.82M | 3.94M |
| Property, Plant & Equipment (Net) | 1.3M | 1.22M | 2.34M | 2.21M | 2.21M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | (176.77K) |
| Total Non-current Assets | 1.3M | 1.22M | 2.34M | 2.21M | 2.03M |
| Total Assets | 2.35M | 2.69M | 3.56M | 13.03M | 5.97M |
| Account Payables | 267.3K | 385.8K | 702.91K | 924.25K | 1.24M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 63.56K | 42.27K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 1M | 0 | 0 |
| Total Current Liabilities | 400.78K | 634.36K | 2.42M | 1.33M | 1.57M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 161.11K | 215K | 140.7K | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 123.58K | 90.37K |
| Total Non-current Liabilities | 748.25K | 678.77K | 1.53M | 1.28M | 1.01M |
| Total Liabilities | 1.15M | 1.31M | 3.94M | 2.61M | 2.57M |
| Common Stock | 12 | 6 | 6 | 8 | 8 |
| Retained Earnings | (2.65M) | (4.05M) | (6.08M) | (11.95M) | (21.1M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.2M | 1.37M | (384.32K) | 10.42M | 3.4M |
| Total Debt | 720.63K | 608.77K | 1.61M | 1.39M | 1.24M |
| Net Debt | 172.82K | 50.2K | 1.55M | (8.33M) | (1.8M) |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.